TRIB2 and Familial prostate cancer: From our unprecedented observations in prostate cancer, it became apparent that TRIB2 is a bona fide driver for enhanced growth and enzalutamide resistance and works via a mechanism involving the promotion of lineage plasticity and transdifferentiation so that prostate cancer cells can overcome the loss of support caused by interruption of the androgenic signaling axis.